Abstract
Background
Injecting drug users represent a high risk group for hepatitis C (HCV) infection. Currently, screening of this group for HCV is inconsistently implemented.
Aim
We designed a HCV assessment algorithm and sought to determine the frequency with which injecting drug users completed the assessment process.
Methods
Prospective study of a HCV assessment algorithm in the setting of a specialist outpatient addiction treatment clinic. Participants consisted of consecutive new attenders over a six-month period with a history of injecting.
Results
Only 21 (18%) of 119 patients reached a satisfactory endpoint of assessment. Forty-eight injectors were tested for antibody to HCV, of whom 26 (54%) tested positive. Thirteen of those with positive test results were no longer attending when the test result became available. Only four of the 19 patients who were referred, attended the on-site hepatology clinic.
Conclusions
Thorough screening of injecting drug users for HCV within one treatment service is difficult. There is a need for explicit policies on this issue involving co-operation between primary care providers and addiction services and hepatoiogy services.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Seymore CA. Screening asymptomatic people at high risk for hepatitis C: The case for.BMJ 1996; 312: 1347–8.
Allison MC, Mills PR. Screening asymptomatic people at high risk for hepatitis C: The case against.BMJ 1996; 312: 1349–50.
Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm.BMJ 1997; 315: 453–8.
Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment.BMJ 1999; 319: 290–1
Ryan KE, MacLennan S, Barbara JAJ, Hewit, PE. Follow up of blood donors positive for antibodies to hepatitis C virus.BMJ 1994; 308: 696–7.
Miller R, Lipman M. HIV pre-test discussion.BMJ 1996; 313: 130.
Gossop M, Johns A, Green L. Opiate withdrawal: inpatient versus outpatient programs and preferred versus random assignment to treatment.BMJ 1986; 293: 103–4.
Sherbourne CD, Hays RD, Ordway L, DiMatteo MR, Kravitz RL. Antecedents of adherence to medical recommendations: results from medical outcomes study.J Behav Med 1992; 15: 447–8.
Dhumeaux D, Doffoel M, Galmiche JP. A French consensus conference on hepatitis C: screening and treatment.J Hepatol 1997; 27: 941–4.
Gordon FD. Cost-effectiveness of screening patients for hepatitis C.Am J Med 1999; 107: 36S-40S.
Leal P, Stein K, Rosenberg W. What is the cost utility of screening for hepatitis C virus in intravenous drug users?J Med Screen 1999; 6: 124–31.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C.Lancet 1997; 349: 825–32.
Smyth BP, McMahon J, O’Connor JJ, Ryan J. Knowledge regarding hepatitis C among injecting drug users. Drugs: Education Prevention and Policy 1999; 6: 257–64.
Smyth BP, McMahon J, O’Connor JJ, Ryan J. The use of primary care services by opiate dependant injecting drug users in Dublin.Eur J Gen Pract 1999; 5: 143–8.
McMahon J, Ryan J, O’Connor JJ, Smyth B. Follow-up of injecting drug users who are not screened for hepatitis C.Ir J Med Sc 1999; 168, Supplement No 3: 18.
Shehab TM, Sonnad SS, Jeffries M, Gunartnum N, Lok AS. Current practice of primary care physicians in the management of patients with hepatitis C.Hepatology 1999; 30: 794–800.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Smyth, B.P., Keenan, E. & O’Connor, J.J. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic. IJMS 169, 129–132 (2000). https://doi.org/10.1007/BF03166917
Issue Date:
DOI: https://doi.org/10.1007/BF03166917